Cargando…

Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI’s “big data for better outcomes” program

Androgen deprivation therapy-based with or without first-generation anti-androgens, was the standard of care for patients with metastatic hormone-sensitive prostate cancer (mHSPC) for decades. However, the development of docetaxel chemotherapy and new androgen receptor-targeted agents, abiraterone a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomez Rivas, Juan, Nicoletti, Rossella, Ibáñez, Laura, Steinbeisser, Carl, de Meulder, Bertrand, Golozar, Asieh, Axelsson, Susan Evans, Snijder, Robert, Bjartell, Anders, Cornford, Philip, Van Hemelrijck, Mieke, Beyer, Katharina, Willemse, Peter-Paul, Murtola, Teemu, Roobol, Monique J., Moreno-Sierra, Jesús, Campi, Riccardo, Gacci, Mauro, Mottet, Nicolas, Merseburger, Axel, Ndow, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688536/
https://www.ncbi.nlm.nih.gov/pubmed/38046899
http://dx.doi.org/10.1097/SP9.0000000000000009
_version_ 1785152189746905088
author Gomez Rivas, Juan
Nicoletti, Rossella
Ibáñez, Laura
Steinbeisser, Carl
de Meulder, Bertrand
Golozar, Asieh
Axelsson, Susan Evans
Snijder, Robert
Bjartell, Anders
Cornford, Philip
Van Hemelrijck, Mieke
Beyer, Katharina
Willemse, Peter-Paul
Murtola, Teemu
Roobol, Monique J.
Moreno-Sierra, Jesús
Campi, Riccardo
Gacci, Mauro
Mottet, Nicolas
Merseburger, Axel
Ndow, James
author_facet Gomez Rivas, Juan
Nicoletti, Rossella
Ibáñez, Laura
Steinbeisser, Carl
de Meulder, Bertrand
Golozar, Asieh
Axelsson, Susan Evans
Snijder, Robert
Bjartell, Anders
Cornford, Philip
Van Hemelrijck, Mieke
Beyer, Katharina
Willemse, Peter-Paul
Murtola, Teemu
Roobol, Monique J.
Moreno-Sierra, Jesús
Campi, Riccardo
Gacci, Mauro
Mottet, Nicolas
Merseburger, Axel
Ndow, James
author_sort Gomez Rivas, Juan
collection PubMed
description Androgen deprivation therapy-based with or without first-generation anti-androgens, was the standard of care for patients with metastatic hormone-sensitive prostate cancer (mHSPC) for decades. However, the development of docetaxel chemotherapy and new androgen receptor-targeted agents, abiraterone acetate and prednisolone, apalutamide , enzalutamide and darolutamide (in combination with docetaxel chemotherapy) has proven that combination of treatments is more effective. Recently, intensification therapy, so-called “triplets”, have emerged in the armamentarium of mHSPC treatment. Metastatic disease is a clinical state that remains poorly understood. The optimal diagnostic and management of patients with mHSPC are changing thanks to the development of new imaging techniques and therapies. The primary objective of this study is to develop and validate a predictive model for the occurrence of symptomatic progression, initiation of new treatments and death amongst patients with mHSPC treated with one of the approved treatment plans, on characteristics present at admission.
format Online
Article
Text
id pubmed-10688536
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-106885362023-12-01 Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI’s “big data for better outcomes” program Gomez Rivas, Juan Nicoletti, Rossella Ibáñez, Laura Steinbeisser, Carl de Meulder, Bertrand Golozar, Asieh Axelsson, Susan Evans Snijder, Robert Bjartell, Anders Cornford, Philip Van Hemelrijck, Mieke Beyer, Katharina Willemse, Peter-Paul Murtola, Teemu Roobol, Monique J. Moreno-Sierra, Jesús Campi, Riccardo Gacci, Mauro Mottet, Nicolas Merseburger, Axel Ndow, James Int J Surg Protoc Protocol Androgen deprivation therapy-based with or without first-generation anti-androgens, was the standard of care for patients with metastatic hormone-sensitive prostate cancer (mHSPC) for decades. However, the development of docetaxel chemotherapy and new androgen receptor-targeted agents, abiraterone acetate and prednisolone, apalutamide , enzalutamide and darolutamide (in combination with docetaxel chemotherapy) has proven that combination of treatments is more effective. Recently, intensification therapy, so-called “triplets”, have emerged in the armamentarium of mHSPC treatment. Metastatic disease is a clinical state that remains poorly understood. The optimal diagnostic and management of patients with mHSPC are changing thanks to the development of new imaging techniques and therapies. The primary objective of this study is to develop and validate a predictive model for the occurrence of symptomatic progression, initiation of new treatments and death amongst patients with mHSPC treated with one of the approved treatment plans, on characteristics present at admission. Lippincott Williams & Wilkins 2023-10-17 /pmc/articles/PMC10688536/ /pubmed/38046899 http://dx.doi.org/10.1097/SP9.0000000000000009 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Protocol
Gomez Rivas, Juan
Nicoletti, Rossella
Ibáñez, Laura
Steinbeisser, Carl
de Meulder, Bertrand
Golozar, Asieh
Axelsson, Susan Evans
Snijder, Robert
Bjartell, Anders
Cornford, Philip
Van Hemelrijck, Mieke
Beyer, Katharina
Willemse, Peter-Paul
Murtola, Teemu
Roobol, Monique J.
Moreno-Sierra, Jesús
Campi, Riccardo
Gacci, Mauro
Mottet, Nicolas
Merseburger, Axel
Ndow, James
Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI’s “big data for better outcomes” program
title Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI’s “big data for better outcomes” program
title_full Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI’s “big data for better outcomes” program
title_fullStr Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI’s “big data for better outcomes” program
title_full_unstemmed Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI’s “big data for better outcomes” program
title_short Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI’s “big data for better outcomes” program
title_sort research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: pioneer imi’s “big data for better outcomes” program
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688536/
https://www.ncbi.nlm.nih.gov/pubmed/38046899
http://dx.doi.org/10.1097/SP9.0000000000000009
work_keys_str_mv AT gomezrivasjuan researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram
AT nicolettirossella researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram
AT ibanezlaura researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram
AT steinbeissercarl researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram
AT demeulderbertrand researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram
AT golozarasieh researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram
AT axelssonsusanevans researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram
AT snijderrobert researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram
AT bjartellanders researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram
AT cornfordphilip researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram
AT vanhemelrijckmieke researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram
AT beyerkatharina researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram
AT willemsepeterpaul researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram
AT murtolateemu researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram
AT roobolmoniquej researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram
AT morenosierrajesus researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram
AT campiriccardo researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram
AT gaccimauro researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram
AT mottetnicolas researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram
AT merseburgeraxel researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram
AT ndowjames researchprotocoltoidentifyprogressionanddeathamongstpatientswithmetastatichormonesensitiveprostatecancertreatedwithavailabletreatmentspioneerimisbigdataforbetteroutcomesprogram